Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
Intra-arterial therapy of neuroendocrine tumour liver metastases: comparing conventional TACE, drug-eluting beads TACE and yttrium-90 radioembolisation as treatment options using a propensity score analysis model.
复制标题
DOI：
10.1007/s00330-017-4856-2
复制
发表时间：
2017-12
影响因子：
5.9
通讯作者：
Geschwind JF
中科院分区：
文献类型：
--
作者：
Do Minh D;Chapiro J;Gorodetski B;Huang Q;Liu C;Smolka S;Savic LJ;Wainstejn D;Lin M;Schlachter T;Gebauer B;Geschwind JF
比较常规经动脉化疗栓塞（cTACE）、药物洗脱微球TACE（DEB-TACE）和90钇放射栓塞（Y 90）治疗胃肠道胰腺（GEP）神经内分泌肿瘤（NELM）肝转移的疗效、生存结局和预后因素。该回顾性分析纳入了2000年至2014年期间接受cTACE（N=122）、DEB-TACE（N=26）或Y 90（N=44）治疗的192例NELM患者（平均年龄58.6岁，男性56%）。根据实体瘤疗效评价标准（RECIST）和世界卫生组织（WHO），使用围手术期MR成像评估放射学治疗反应。生存分析包括倾向评分分析（PSA）、中位总生存期（MOS）、肝脏无进展生存期、Kaplan-Meier对数秩检验以及单因素和多因素考克斯比例风险模型（MVA）。整个研究人群的MOS为28.8个月。cTACE、DEB-TACE和Y 90的MOS分别为33.8个月、21.7个月和23.6个月。根据MVA，与DEB-TACE（p= 0.04）或Y 90（p= 0.032）相比，cTACE的MOS显著更长。初始cTACE、DEB-TACE和Y 90后的5年生存率分别为28.2%、10.3%和18.5%。根据PSA，我们的研究表明，与DEB-TACE和Y 90相比，接受cTACE治疗的患者具有显著的生存获益。该数据支持将cTACE作为不可切除NELM患者的主要动脉内治疗选择的治疗决策，除非证明并非如此。
To compare efficacy, survival outcome and prognostic factors of conventional transarterial chemoembolization (cTACE), drug-eluting beads TACE (DEB-TACE) and 90Yttrium-radioembolization (Y90) for the treatment of liver metastases from gastro-entero-pancreatic (GEP) neuroendocrine tumors (NELM). This retrospective analysis included 192 patients (58.6years mean age, 56%men) with NELM treated with cTACE(N=122), DEB-TACE(N=26), or Y90(N=44) between 2000 and 2014. Radiologic response to therapy was assessed according to Response Evaluation Criteria in Solid Tumors (RECIST) and World Health Organization (WHO) using peri-procedural MR imaging. Survival analysis included Propensity score analysis (PSA), median overall survival (MOS), hepatic progression-free survival, Kaplan-Meier using log-rank test and the uni-and multivariate Cox proportional hazards model (MVA). MOS of the entire study population was 28.8months. As for cTACE, DEB-TACE and Y90, MOS was 33.8months, 21.7months and 23.6months, respectively. According to the MVA, cTACE demonstrated a significantly longer MOS as compared to DEB-TACE(p=.04) or Y90(p=.032). The five-year survival rate after initial cTACE, DEB-TACE and Y90 was 28.2%, 10.3% and 18.5%, respectively. Upon PSA, our study suggests significant survival benefits for patients treated with cTACE as compared to DEB-TACE and Y90. This data supports the therapeutic decision for cTACE as the primary intra-arterial therapy option in patients with unresectable NELM until proven otherwise.
登录
查看更多内容
影响因子：
2.9
作者：
Bhagat, Nikhil;Reyes, Diane K.;Lin, Mingde;Kamel, Ihab;Pawlik, Timothy M.;Frangakis, Constantine;Geschwind, J. F.
通讯作者：
Geschwind, J. F.
DOI：
10.1016/j.jvir.2008.01.030
发表时间：
2008-06-01
影响因子：
2.9
作者：
de Baere, Thierry;Deschamps, Frederic;Hechellhammer, Lukas
通讯作者：
Hechellhammer, Lukas
影响因子：
1.4
作者：
Gupta, Sanjay
通讯作者：
Gupta, Sanjay
影响因子：
6.2
作者：
Gupta, S;Johnson, MM;Yao, JC
通讯作者：
Yao, JC
影响因子：
2.9
作者：
Liapi, Eleni;Geschwind, Jean-Francois H.
通讯作者：
Geschwind, Jean-Francois H.